BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30880199)

  • 1. Clinical and Pathologic Features and Prognostic Factors for Recurrent Gliomas.
    Li J; Niu X; Gan Y; Yang Y; Wang T; Zhang H; Liu Y; Mao Q
    World Neurosurg; 2019 Aug; 128():e21-e30. PubMed ID: 30880199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characteristics of Thalamic Gliomas in Adults.
    Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
    J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
    Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
    Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
    Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
    Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor location and patient age predict biological signatures of high-grade gliomas.
    Altieri R; Zenga F; Ducati A; Melcarne A; Cofano F; Mammi M; Di Perna G; Savastano R; Garbossa D
    Neurosurg Rev; 2018 Apr; 41(2):599-604. PubMed ID: 28856492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic value of the WEE1 kinase in gliomas.
    Music D; Dahlrot RH; Hermansen SK; Hjelmborg J; de Stricker K; Hansen S; Kristensen BW
    J Neurooncol; 2016 Apr; 127(2):381-9. PubMed ID: 26738845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.
    Fogli A; Demattei MV; Corset L; Vaurs-Barrière C; Chautard E; Biau J; Kémény JL; Godfraind C; Pereira B; Khalil T; Grandin N; Arnaud P; Charbonneau M; Verrelle P
    J Neurooncol; 2017 Nov; 135(2):381-390. PubMed ID: 28755323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic Findings and Clinical Course of Midline Paraventricular Gliomas Diagnosed Using a Neuroendoscope.
    Fukami S; Nakajima N; Okada H; Akimoto J; Miki T; Fukuhara H; Shishido-Hara Y; Nagao T; Tsuda M; Kohno M
    World Neurosurg; 2018 Jun; 114():e366-e377. PubMed ID: 29530692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers.
    Cordier D; Gozé C; Schädelin S; Rigau V; Mariani L; Duffau H
    J Neurooncol; 2015 Jan; 121(1):185-93. PubMed ID: 25261925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of p53, mgmt and egfr in brain glioma and clinical significance.
    Lin T; Wang M; Liang HS; Liu EZ
    J Biol Regul Homeost Agents; 2015; 29(1):143-9. PubMed ID: 25864751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.
    Sasaki T; Fukai J; Kodama Y; Hirose T; Okita Y; Moriuchi S; Nonaka M; Tsuyuguchi N; Terakawa Y; Uda T; Tomogane Y; Kinoshita M; Nishida N; Izumoto S; Nakajima Y; Arita H; Ishibashi K; Shofuda T; Kanematsu D; Yoshioka E; Mano M; Fujita K; Uematsu Y; Nakao N; Mori K; Kanemura Y
    J Neurooncol; 2018 Nov; 140(2):329-339. PubMed ID: 30076584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
    Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
    Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biology of high-grade gliomas: what should the clinician know?
    Hofer S; Rushing E; Preusser M; Marosi C
    Chin J Cancer; 2014 Jan; 33(1):4-7. PubMed ID: 24325789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological factors predictive of postoperative seizures in patients with gliomas.
    Yang P; Liang T; Zhang C; Cai J; Zhang W; Chen B; Qiu X; Yao K; Li G; Wang H; Jiang C; You G; Jiang T
    Seizure; 2016 Feb; 35():93-9. PubMed ID: 26808114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiomic features predict Ki-67 expression level and survival in lower grade gliomas.
    Li Y; Qian Z; Xu K; Wang K; Fan X; Li S; Liu X; Wang Y; Jiang T
    J Neurooncol; 2017 Nov; 135(2):317-324. PubMed ID: 28900812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.